Novel inflammatory targets are already being exploited in the management of IBD while a significant number are currently under investigation. This section of the Knowledge Centre describes the inflammatory targets currently used in the clinic as well as those at an advanced stage of development in the search for improved ulcerative colitis and Crohn’s disease therapies.
Read about interleukins-12 and -13 and how they can produce pro-inflammatory responses through the JAK signalling pathway.
Learn how integrins on the surface of leucocytes can facilitate "immune cell homing". How can this process be targeted by treatment?
Discover how JAKs are involved in a variety of processes, including immunity, with different cytokines signalling through different JAK members to modulate immune responses.
Find out why the overexpression of SMAD7 can cause inflammation in IBD through its relationship with TGF-β1.
Learn how sphingosine 1-phosphate binding to S1P1 can lead to lymphocyte release, contributing to gut inflammation.
Learn how this cytokine has become the target of standard therapies due to its role as one of the main pro-inflammatory agents in IBD.
Alternatively login via
Back to epgonline.org